Evaluation of Recombinant Herpes Zoster Vaccine for Primary Immunization of Varicella-seronegative Transplant Recipients

Arnaud G L'Huillier, Cedric Hirzel, Victor H Ferreira, Matthew Ierullo, Terrance Ku, Nazia Selzner, Jeffrey Schiff, Stephen Juvet, Congrong Miao, D Scott Schmid, Atul Humar, Deepali Kumar, Arnaud G L'Huillier, Cedric Hirzel, Victor H Ferreira, Matthew Ierullo, Terrance Ku, Nazia Selzner, Jeffrey Schiff, Stephen Juvet, Congrong Miao, D Scott Schmid, Atul Humar, Deepali Kumar

Abstract

Background: Immunization of varicella-zoster virus (VZV)-seronegative solid organ transplant (SOT) patients using the live-attenuated varicella vaccine is generally contraindicated, leaving no widely applicable immunization option. The recombinant subunit herpes zoster vaccine (RZV) is indicated for VZV-seropositive persons to prevent shingles but could potentially also protect VZV-seronegative persons against varicella. We performed a safety and immunogenicity evaluation of RZV in VZV-seronegative SOT recipients as an option for protection.

Methods: VZV-seronegative adult SOT patients with no history of varicella/shingles vaccine or disease were given 2 doses of RZV vaccine 2-6 mo apart. Blood was drawn prevaccination (V1), before the second dose (V2), and 4 wk after the second dose (V3). Humoral immunity (anti-glycoprotein E) and cell-mediated immunity were evaluated, with polyfunctional cells defined as cells producing ≥2 cytokines.

Results: Among 31 eligible VZV-seronegative SOT patients screened, 23 were enrolled. Median age was 38 y and median time since transplant procedure was 3.8 y. The most frequent transplant types were liver (35%) and lung (30%). Median anti-glycoprotein E levels significantly increased from V1 to V3 (P = 0.001) and V2 to V3 (P < 0.001), even though only 55% had a positive seroresponse. Median polyfunctional CD4 T-cell counts increased from V1 to V2 (54/106 versus 104/106 cells; P = 0.041) and from V2 to V3 (380/106; P = 0.002). Most adverse events were mild with no rejection episodes.

Conclusions: RZV was safe and elicited significant humoral and cellular responses in VZV-seronegative SOT patients and has the potential to be considered as a preventive strategy against primary varicella.

Trial registration: ClinicalTrials.gov NCT03685682.

Conflict of interest statement

D.K. has received clinical trials grant and consulting fees from GSK. The other authors declare no conflicts of interest.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

References

    1. Feldhoff CM, Balfour HH Jr, Simmons RL, et al. Varicella in children with renal transplants. J Pediatr. 1981;98:25–31.
    1. Lynfield R, Herrin JT, Rubin RH. Varicella in pediatric renal transplant recipients. Pediatrics. 1992;90(Pt 1):216–220.
    1. Fehr T, Bossart W, Wahl C, et al. Disseminated varicella infection in adult renal allograft recipients: four cases and a review of the literature. Transplantation. 2002;73:608–611.
    1. Gourishankar S, McDermid JC, Jhangri GS, et al. Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era. Am J Transplant. 2004;4:108–115.
    1. Fuks L, Shitrit D, Fox BD, et al. Herpes zoster after lung transplantation: incidence, timing, and outcome. Ann Thorac Surg. 2009;87:423–426.
    1. Rubin LG, Levin MJ, Ljungman P, et al.; Infectious Diseases Society of America. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014;58:e44–100.
    1. Danziger-Isakov L, Kumar D; AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019;33:e13563.
    1. Lal H, Cunningham AL, Godeaux O, et al.; ZOE-50 Study Group. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med. 2015;372:2087–2096.
    1. Vink P, Ramon Torrell JM, Sanchez Fructuoso A, et al.; Z-041 Study Group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase 3, randomized clinical trial. Clin Infect Dis. 2020;70:181–190.
    1. Stadtmauer EA, Sullivan KM, Marty FM, et al. A phase ½ study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients. Blood. 2014;124:2921–2929.
    1. Berkowitz EM, Moyle G, Stellbrink HJ, et al.; Zoster-015 HZ/su Study Group. Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2015;211:1279–1287.
    1. Chlibek R, Bayas JM, Collins H, et al. Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age. J Infect Dis. 2013;208:1953–1961.
    1. Cunningham AL, Heineman TC, Lal H, et al.; ZOE-50/70 Study Group. Immune responses to a recombinant glycoprotein E herpes zoster vaccine in adults aged 50 years or older. J Infect Dis. 2018;217:1750–1760.
    1. Reynolds MA, Kruszon-Moran D, Jumaan A, et al. Varicella seroprevalence in the U.S.: data from the National Health and Nutrition Examination Survey, 1999-2004. Public Health Rep. 2010;125:860–869.
    1. Moris P, van der Most R, Leroux-Roels I, et al. H5N1 influenza vaccine formulated with AS03 A induces strong cross-reactive and polyfunctional CD4 T-cell responses. J Clin Immunol. 2011;31:443–454.
    1. Salvadori M, Holzer H, de Mattos A, et al.; ERL B301 Study Groups. Enteric-coated mycophenolate sodium is therapeutically equivalent to mycophenolate mofetil in de novo renal transplant patients. Am J Transplant. 2004;4:231–236.
    1. Suresh S, Upton J, Green M, et al. Live vaccines after pediatric solid organ transplant: proceedings of a consensus meeting, 2018. Pediatr Transplant. 2019;23:e13571.
    1. Litwin V, Jackson W, Grose C. Receptor properties of two varicella-zoster virus glycoproteins, gpI and gpIV, homologous to herpes simplex virus gE and gI. J Virol. 1992;66:3643–3651.
    1. Zhu Z, Gershon MD, Hao Y, et al. Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi network. J Virol. 1995;69:7951–7959.
    1. Geel AL, Landman TS, Kal JA, et al. Varicella zoster virus serostatus before and after kidney transplantation, and vaccination of adult kidney transplant candidates. Transplant Proc. 2006;38:3418–3419.
    1. Chaves Tdo S, Lopes MH, de Souza VA, et al. Seroprevalence of antibodies against varicella-zoster virus and response to the varicella vaccine in pediatric renal transplant patients. Pediatr Transplant. 2005;9:192–196.
    1. Breuer J, Schmid DS, Gershon AA. Use and limitations of varicella-zoster virus-specific serological testing to evaluate breakthrough disease in vaccinees and to screen for susceptibility to varicella. J Infect Dis. 2008;197(Suppl 2):S147–S151.
    1. Haberthur K, Engelmann F, Park B, et al. CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection. Plos Pathog. 2011;7:e1002367.
    1. Kleemann P, Distler E, Wagner EM, et al. Varicella-zoster virus glycoproteins B and E are major targets of CD4+ and CD8+ T cells reconstituting during zoster after allogeneic transplantation. Haematologica. 2012;97:874–882.
    1. Polcicova K, Goldsmith K, Rainish BL, et al. The extracellular domain of herpes simplex virus gE is indispensable for efficient cell-to-cell spread: evidence for gE/gI receptors. J Virol. 2005;79:11990–12001.
    1. Godfrey DI, Rossjohn J, McCluskey J. The fidelity, occasional promiscuity, and versatility of T cell receptor recognition. Immunity. 2008;28:304–314.
    1. Natori Y, Shiotsuka M, Slomovic J, et al. A double-blind, randomized trial of high-dose vs standard-dose influenza vaccine in adult solid-organ transplant recipients. Clin Infect Dis. 2018;66:1698–1704.
    1. Shodell M, Shah K, Siegal FP. Circulating human plasmacytoid dendritic cells are highly sensitive to corticosteroid administration. Lupus. 2003;12:222–230.
    1. Katerinis I, Hadaya K, Duquesnoy R, et al. De novo anti-HLA antibody after pandemic H1N1 and seasonal influenza immunization in kidney transplant recipients. Am J Transplant. 2011;11:1727–1733.
    1. Cohet C, Haguinet F, Dos Santos G, et al. Effect of the adjuvanted (AS03) A/H1N1 2009 pandemic influenza vaccine on the risk of rejection in solid organ transplant recipients in England: a self-controlled case series. BMJ Open. 2016;6:e009264.
    1. Dos Santos G, Haguinet F, Cohet C, et al. Risk of solid organ transplant rejection following vaccination with seasonal trivalent inactivated influenza vaccines in England: a self-controlled case-series. Vaccine. 2016;34:3598–3606.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe